a

XtalPi and CK Life Sciences collaborate on research and development in the development of AI-assisted tumor vaccines, opening a new paradigm for scientific innovation.

XtalPi and CK Life Sciences collaborate on research and development in the development of AI-assisted tumor vaccines, opening a new paradigm for scientific innovation.

Currently, there are only two therapeutic oncology vaccines – sipuleucel-T for melanoma and Bacillus Calmette-Guérin (BCG) for bladder cancer, as well as preventive oncology vaccines against HPV infection and hepatitis B infection approved by the US Food and Drug Administration (administration). Food and Drugs). Recently, several other tumor vaccines have entered clinical development and evidence of their efficacy is beginning to emerge.

According to Mordor Intelligence, the size of the global cancer vaccine market $6.79 billion in 2021 and will increase at a CAGR of 11.53% from 2022 to 2026. The projected market size by 2026 will be approximately 12 billion US dollars.

Currently, the design and preclinical development of oncolytic vaccines is complex and lengthy, which hinders the efficiency and success rate of oncolytic vaccine research and development.

By integrating XtalPi’s industry expertise in AI computation and robotic automation, this collaboration aims to build an AI tumor vaccine research and development platform which applies advanced AI algorithms and high-accuracy molecular modeling to predict and design a variety of tumor vaccines that can activate specific immune responses to kill tumors. . Tumor vaccines will be screened and validated through automated trials, and by incorporating computational feedback to improve activity and efficacy, the platform is expected to generate preclinical tumor vaccine candidate compounds with robust immunogenic activity.

Dr. Shuhao WenCo-Founder and Chairman of XtalPi, comments: “As a company based in Hetao Shenzhen-Hong Kong Science and Technology Innovation Zone, XtalPi is committed to achieving synergies between Shenzhen And the Hong Kong By creating a new paradigm for innovation in the Greater Bay Area. Powered by the latest technological advances in automation, AI is accelerating more innovative and diverse areas of drug research and development. Together with CK Life Sciences, we are committed to overcoming traditional limitations and discovering diverse applications of cutting-edge technologies. We believe the AI ​​cancer vaccine platform developed by CK Life Sciences and XtalPi will inspire the global scientific community to advance vaccine research and development and accelerate key development stages of cancer vaccines. We are confident that this cooperation will greatly facilitate the exchange of scientific research in the Greater Bay Area.”

Dr. Melvin TohVice President and Chief Scientific Officer of CK Life Sciences, commented: “The research and development of oncology vaccines is one of the main development directions of CK Life Sciences. Cooperation with XtalPi will implement XtalPi artificial intelligence algorithm, molecular modeling, and automated experiments to accelerate research and development, and improve the rate of success, increasing the efficacy of oncology vaccines.”

About XtalPi

Founded in 2014, the founders of XtalPi recognized a common drug development hurdle related to solid polymorphism, which can be successfully addressed by predictions of quantum physics. Since then, XtalPi has maintained its focus on identifying and then attacking traditional bottlenecks in biopharmaceutical R&D through innovative technologies. With significant capital investments in automation and personnel, XtalPi now has four locations worldwide and employs approximately 1,000 employees. XtalPi has participated in collaborative research with nearly all of the 20 largest pharmaceutical companies in the world. Its ID4 platform combines physics-based simulations, experimental validation, optimization, and automation for rapid tuning, and machine learning to continually improve prediction accuracy and process efficiency.

About CK Life Sciences

CK Life Sciences (stock code: 0775) is listed on the Stock Exchange Hong Kong. Carrying a mission to improve quality of life, CK Life Sciences is engaged in the business of researching, developing, manufacturing, marketing, selling, and investing in products and assets that fall into three primary categories – Nutrients, Pharmaceuticals, and Agriculture-Related. CK Life Sciences is a member of the CK Hutchison Group.

Media contact:
Ruyu Wang
[email protected]
(617) 717-9867

Source: XtalPi Inc.


#XtalPi #Life #Sciences #collaborate #research #development #development #AIassisted #tumor #vaccines #opening #paradigm #scientific #innovation

Leave a Comment

Your email address will not be published. Required fields are marked *